Key result
Incomplete stent apposition persisted at 8-12 months in 26% of everolimus-eluting stents and 38% of sirolimus-eluting stents, although the size significantly decreased during follow-up.
Absolute Event Rate: 26% vs 38%
Acute incomplete stent apposition is universally observed post-PCI with EES and SES but significantly decreases in size and persists in only a minority of cases at 8-12 months.
In their article, Shimamura et al. report that incomplete stent apposition (ISA) was observed in all 38 everolimus-eluting stents (EES) and all 39 sirolimus-eluting stents (SES) post-percutaneous coronary intervention (PCI) (measuring 315 ± 94 µm and 0.50 ± 0.24 mm2 in EES and 308 ± 119 µm and 0.95 ± 0.70 mm2 in SES), that it persisted in 26% of EES and 38% of SES at 8–12 months although the size of the ISA significantly decreased during follow-up in both groups (to 110 ± 165 µm and 0.17 ± 0.27 mm2 in EES and 143 ± 175 µm and 0.41 ± 0.66 mm2 in SES), and that the best post-stenting optical coherence tomographic (OCT)-measured ISA distance that predicted late-persistent ISA was …
No takes yet. Share an insight, caveat, or question.
G. S. Mintz (2014) conducted an editorial in Post-percutaneous coronary intervention (PCI) (n=77). Everolimus-eluting stents (EES) vs. Sirolimus-eluting stents (SES) was evaluated on Late-persistent incomplete stent apposition (ISA) at 8-12 months. Incomplete stent apposition persisted at 8-12 months in 26% of everolimus-eluting stents and 38% of sirolimus-eluting stents, although the size significantly decreased during follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: